Ujjwal Neogi1,2, Kamalendra Singh1,3,4,2, Shambhu G Aralaguppe1, Leonard C Rogers3, Duncan T Njenda1, Stefan G Sarafianos3,4, Bo Hejdeman5, Anders Sönnerborg1,6. 1. Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden. 2. Ujjwal Neogi and Kamalendra Singh contributed equally in the article. 3. Department of Molecular Microbiology and Immunology. 4. Bond Life Sciences Center, University of Missouri, Columbia, Missouri, USA. 5. Department of Infectious Diseases, Gay Men Health, South Hospital. 6. Unit of Infectious Diseases, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Abstract
OBJECTIVE: To determine the antiretroviral activity of the integrase strand transfer inhibitors (INSTIs), raltegravir (RAL), elvitegravir (EVG), dolutegravir (DTG), cabotegravir (CAB) and bictegravir (BIC), against different subtypes as well as primary and acquired drug resistance mutations (DRMs) in a patient-cohort infected with diverse subtypes. DESIGN: Biochemical and virological drug sensitivity analyses using patient-derived HIV type 1 (HIV-1) genes and cross-sectional/longitudinal clinical study. METHODS: Assays for 50% inhibition of 3'-end processing (IC50-3EP), strand transfer (IC50-ST) and drug sensitivity for five INSTIs were done using patient-derived integrase or gag-pol genes from subtypes A1, B, C, 01_AE and 02_AG. Integrase from INSTI-naive (n = 270) and experienced (n = 96) patients were sequenced. RESULTS: RAL had higher IC50-ST than the other INSTIs for all subtypes. EVG had higher IC50-ST for HIV 1 subtype C (P < 0.05) and 02_AG (P < 0.05) than HIV 1 subtype B (HIV-1B). DTG showed lower IC50-ST in HIV 1 subtype C than HIV-1B (P = 0.003). In CAB , the non-B subtypes showed lower IC50-ST (P < 0.05) than HIV-1B. In BIC, lower IC50-ST in 01_AE (P = 0.017) and 02_AG (P = 0.045) than HIV-1B. In drug sensitivity assay, inhibiting virus replication by 50% for DTG [median (IQR) 2.14 (1.3-2.56)], CAB [1.68 (1.34-2.55)] and BIC [1.07 (0.22-2.53)] were lower than RAL and EVG. One patient had a primary DRMs (0.3%, 1/270), but 17 (6.3%) had one major accessory DRM, of which 12 were E157Q. CONCLUSION: The equal or higher potency in non-B subtypes of DTG, CAB and BIC compared with RAL and EVG confirms their suitability for use in countries dominated by non-B subtypes. Any impact of the high prevalence of major accessory mutations, especially E157Q, requires long-term follow-up studies.
OBJECTIVE: To determine the antiretroviral activity of the integrase strand transfer inhibitors (INSTIs), raltegravir (RAL), elvitegravir (EVG), dolutegravir (DTG), cabotegravir (CAB) and bictegravir (BIC), against different subtypes as well as primary and acquired drug resistance mutations (DRMs) in a patient-cohort infected with diverse subtypes. DESIGN: Biochemical and virological drug sensitivity analyses using patient-derived HIV type 1 (HIV-1) genes and cross-sectional/longitudinal clinical study. METHODS: Assays for 50% inhibition of 3'-end processing (IC50-3EP), strand transfer (IC50-ST) and drug sensitivity for five INSTIs were done using patient-derived integrase or gag-pol genes from subtypes A1, B, C, 01_AE and 02_AG. Integrase from INSTI-naive (n = 270) and experienced (n = 96) patients were sequenced. RESULTS:RAL had higher IC50-ST than the other INSTIs for all subtypes. EVG had higher IC50-ST for HIV 1 subtype C (P < 0.05) and 02_AG (P < 0.05) than HIV 1 subtype B (HIV-1B). DTG showed lower IC50-ST in HIV 1 subtype C than HIV-1B (P = 0.003). In CAB , the non-B subtypes showed lower IC50-ST (P < 0.05) than HIV-1B. In BIC, lower IC50-ST in 01_AE (P = 0.017) and 02_AG (P = 0.045) than HIV-1B. In drug sensitivity assay, inhibiting virus replication by 50% for DTG [median (IQR) 2.14 (1.3-2.56)], CAB [1.68 (1.34-2.55)] and BIC [1.07 (0.22-2.53)] were lower than RAL and EVG. One patient had a primary DRMs (0.3%, 1/270), but 17 (6.3%) had one major accessory DRM, of which 12 were E157Q. CONCLUSION: The equal or higher potency in non-B subtypes of DTG, CAB and BIC compared with RAL and EVG confirms their suitability for use in countries dominated by non-B subtypes. Any impact of the high prevalence of major accessory mutations, especially E157Q, requires long-term follow-up studies.
Authors: Shambhu G Aralaguppe; Abu Bakar Siddik; Ashokkumar Manickam; Anoop T Ambikan; Milner M Kumar; Sunjay Jude Fernandes; Wondwossen Amogne; Dhinoth K Bangaruswamy; Luke Elizabeth Hanna; Anders Sonnerborg; Ujjwal Neogi Journal: J Virol Methods Date: 2016-07-19 Impact factor: 2.014
Authors: Rami Kantor; Laura Smeaton; Saran Vardhanabhuti; Sarah E Hudelson; Carol L Wallis; Srikanth Tripathy; Mariza G Morgado; Shanmugham Saravanan; Pachamuthu Balakrishnan; Marissa Reitsma; Stephen Hart; John W Mellors; Elias Halvas; Beatriz Grinsztejn; Mina C Hosseinipour; Johnstone Kumwenda; Alberto La Rosa; Umesh G Lalloo; Javier R Lama; Mohammed Rassool; Breno R Santos; Khuanchai Supparatpinyo; James Hakim; Timothy Flanigan; Nagalingeswaran Kumarasamy; Thomas B Campbell; Susan H Eshleman Journal: Clin Infect Dis Date: 2015-02-13 Impact factor: 9.079
Authors: Kendra E Hightower; Ruolan Wang; Felix Deanda; Brian A Johns; Kurt Weaver; Yingnian Shen; Ginger H Tomberlin; H Luke Carter; Timothy Broderick; Scott Sigethy; Takahiro Seki; Masanori Kobayashi; Mark R Underwood Journal: Antimicrob Agents Chemother Date: 2011-08-01 Impact factor: 5.191
Authors: Tomas Doyle; David T Dunn; Francesca Ceccherini-Silberstein; Carmen De Mendoza; Frederico Garcia; Erasmus Smit; Esther Fearnhill; Anne-Genevieve Marcelin; Javier Martinez-Picado; Rolf Kaiser; Anna Maria Geretti Journal: J Antimicrob Chemother Date: 2015-08-26 Impact factor: 5.790
Authors: Robert A Smith; Dana N Raugi; Vincent H Wu; Christopher G Zavala; Jennifer Song; Khardiata Mbaye Diallo; Moussa Seydi; Geoffrey S Gottlieb Journal: Antimicrob Agents Chemother Date: 2019-04-25 Impact factor: 5.191
Authors: Kyle J Hill; Leonard C Rogers; Duncan T Njenda; Donald H Burke; Stefan G Sarafianos; Anders Sönnerborg; Ujjwal Neogi; Kamalendra Singh Journal: AIDS Date: 2019-03-01 Impact factor: 4.177
Authors: Emmanuel Ndashimye; Yue Li; Paul S Reyes; Mariano Avino; Abayomi S Olabode; Cissy M Kityo; Fred Kyeyune; Immaculate Nankya; Miguel E Quiñones-Mateu; Stephen D Barr; Eric J Arts Journal: J Antimicrob Chemother Date: 2021-10-11 Impact factor: 5.758